Atropine Sulfate

Atropine Sulfate Injection is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life threatening muscarinic effects. ( 1 )

None. None. ( 4 )

Tachycardia ( 5.1 ) Glaucoma ( 5.2 ) Pyloric obstruction ( 5.3 ) Worsening urinary retention ( 5.4 ) Viscid bronchial plugs ( 5.5 )

5.1Tachycardia When

the recurrent use of atropine is essential in patients with coronary artery disease, the total dose should be restricted to 2 to 3 mg (maximum 0.03 to 0.04 mg/kg) to avoid the detrimental effects of atropine-induced tachycardia on myocardial oxygen demand.

5.2Acute Glaucoma

Atropine may precipitate acute glaucoma.

5.3Pyloric Obstruction

Atropine may convert partial organic pyloric stenosis into complete obstruction.

5.4Complete Urinary Retention

Atropine may lead to complete urinary retention in patients with prostatic hypertrophy.

5.5Viscid Plugs

Atropine may cause inspissation of bronchial secretions and formation of viscid plugs in patients with chronic lung disease.

Mexiletine: Decreases rate of mexiletine absorption. ( 7.1 )

7.1Mexiletine Atropine Sulfate